Atherectomy Devices Market By Type (Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy, Laser Atherectomy), By Application (Peripheral Vascular Applications, Cardiovascular Applications, Neurovascular Applications), By End-User (Hospitals and Surgical Centres, Ambulatory Care Centres, Other End Users), By Geography, Segment revenue estimation, Forecast, 2021-2030

Published On: Apr-2022 Base Year: 2021 No Of Pages: 135 Historical Data: 2017 - 2020 Formats: PDF Report ID: 67760273

Industry Report and Statistics

The global atherectomy devices market will witness a robust CAGR of 7.34%, valued at $1.02 billion in 2021, expected to appreciate and reach $2.01 billion by 2030, confirms Strategic Market Research. North America had the highest industry share of 75.83%. Atherectomy is a method that uses a catheter with a sharp blade on the end that removes plaque from a blood vessel. The patient is first sedated. The surgeon then gently inserts the catheter into the patient’s body, usually in the groin or upper thigh. The catheter is then guided gently through the blood vessels into the heart. Once the catheter is at the required position, dye is injected through the catheter into the coronary arteries. An X-ray is conducted to determine the blocked or narrowed area. The surgeon uses tiny blades or lasers attached to the end of the catheter to remove plaque. A study shows over 190,000 atherectomy procedures are performed yearly in the US. This number is expected to surge owing to the increasing prevalence of atherosclerosis among the masses.

Drivers - Rising Prevalence of Diseases and Geriatric Population, Growing Preference for minimally invasive surgical procedures, and Higher Success Rate

The world's population has a rising frequency of arterial diseases (peripheral artery disease, coronary artery disease). According to the NCBI, more than 200 million people have peripheral artery disease (PAD) worldwide. In addition, there has been a notable rise in the geriatric population. According to Statistics Canada, 18.5% of the Canadian population will be 65 and older in 2021 and more prone to coronary artery disease. This has increased the demand for Atherectomy devices, thus augmenting the industry growth.

Recently, doctors and patients have increased the adoption of minimally invasive procedures like atherectomy. Hence, the demand for Atherectomy devices has increased, which extensively accelerates the atherectomy devices market growth. According to an American Heart Association (AHA) study, Atherectomy devices were 94.7% successful in treating patients. Thus, market growth is expected to increase rapidly with a higher success rate.

Restraints - High Costs, High Restenosis Rate

The high costs of atherectomy force patients to prefer other methods of treatment. According to an NCBI study, the average angioplasty cost is around USD 7300. In contrast, the average cost of atherectomy is USD 9300. The high costs impact the demand for atherectomy, which impedes the market growth.
Atherectomy has a high success rate, but its high restenosis rate force patients to opt for other treatment methods, thus slowing down the market growth. According to a study published in AHA, atherectomy had a 37.7% restenosis rate.

Opportunities - Improved Technologies

With newer and improved Atherectomy devices, the industry growth can be accelerated to provide further opportunities for growth. Processes like Percutaneous Revascularisation using treatment principles such as optical coherence tomography and interventional radiology could be used to improve Atherectomy devices. In addition, Atherectomy systems like thrombectomy devices and Vitrectomy devices could also be used. According to Healthline, the success rate of vitrectomy is 90%, even for patients over 60 years old.

Market Analysis Of Different Segments Covered in the Report

Based on Type

Directional Coronary Atherectomy
Rotational Atherectomy
Orbital Atherectomy
Laser Atherectomy

Based on Application

Peripheral Vascular Applications
Cardiovascular Applications
Neurovascular Applications

Based on End-User

Hospitals and Surgical Centres
Ambulatory Care Centres
Other End Users

Atherectomy Devices Market Based on Application

Regional Coverage Analysis

North America

United States of America
Canada
Mexico
Rest of North America

Europe

United Kingdom
Germany
France
Italy
Rest of Europe

Asia-Pacific

Japan
China
India
Rest of APAC

LAMEA

Argentina
Brazil
UAE
Rest of LAMEA

Segments Analysis & Insights

Based on type, the orbital atherectomy segment held the largest industry size, with almost 30% in 2020. Orbital atherectomy is an adjunctive technique used for the lesion preparation of calcified plaque. This is done to avoid percutaneous coronary intervention and peripheral percutaneous endovascular interventions. According to a research study published by the American Heart Association, the success rate of orbital atherectomy was 99%.

On the other hand, the laser atherectomy market is expected to grow the fastest with a CAGR of 7% due to its suitability for clinical benefits offered and ongoing increasing developments in directional Atherectomy technology. According to a study, 24% of all atherectomy procedures were done using a laser.

The peripheral vascular applications segment is expected to contribute a significant market share based on application. This segment is expected to register the maximum CAGR of 6.71% due to its attribution to increasing acceptance of atherectomy to treat cardiac and peripheral vascular diseases over the forecasted period.

Based on the end-user, hospitals and surgical centers are estimated to have the highest revenue share in the global Atherectomy devices market, with a revenue CAGR of more than 6.63% during the forecasted period because of an observed rise in Atherectomy acceptability for the treatment of cardiac and peripheral vascular diseases throughout the forecasted period.

The North American region had the highest market share of 75.83%. The rising number of cardiovascular, neurovascular, and peripheral diseases, better technology, and more trained medical professionals in atherectomy contributed to the industry's growth. According to the CDC, around 6.5 million people aged 40 and older have peripheral artery disease in the USA. Asia-Pacific is forecasted to have the maximum industry growth from 2020 to 2030, with a CAGR of 8.2%. Socioeconomic changes, unhealthy diet, liquor intake, smoking, and demographic aging have increased target diseases and increased demand for the overall market. According to an NCBI study, 4.77 million Indians will have cardiovascular diseases in 2020.

Atherectomy Devices Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
The market size value in 2021	USD 1.06 billion
The revenue forecast in 2030	USD 2.01 billion
Growth rate	CAGR of approximately 8.2%
The base year for estimation	2021
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By Type, By Application, By End-Use, By Region
By Type	Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy, Laser Atherectomy
By Application	Peripheral Vascular Applications, Cardiovascular Applications, Neurovascular Applications
By End-Use	Hospitals and Surgical Centres, Ambulatory Care Centres, Other End Users
By Region	Asia Pacific, North America, Europe, LAMEA
Country Scope	United States of America, Canada, Mexico, United Kingdom, Germany, France, Italy, Japan, India, China, Argentina, Brazil, United Arab Emirates
Company Usability Profiles	Abbott Laboratories, Boston Scientific Corporation, Medtronic, Becton, Dickinson and Company (BD Interventional), Koninklijke Philips N.V., Avinger, Inc., Rex Medical, AngioDynamics
Cost & acquiring options	Get hold of customized purchase options to fulfill your niche research needs.

Atherectomy Devices Market Competitive Landscape Analysis

The industry is moderately competitive, with many key players in the market. Some major companies that are currently operating in this market are:

Abbott Laboratories
Boston Scientific Corporation
Medtronic
Becton, Dickinson, and Company (BD Interventional)
Koninklijke Philips N.V.
Avinger, Inc.
Rex Medical
AngioDynamics

Atherectomy Devices Market Based on Region

Recent Developments

On August 3rd, 2022, AngioDynamics announced that it had received FDA approval for launching its highly advanced Auryon-Atherectomy System. AngioDynamics is further planning to launch Auryon System’s 2.35 mm and 2.0 mm catheters to treat arterial thrombosis. Both the catheters are highly efficient as atherectomy conducting devices and can also be used to treat ISR /In-Stent Restenosis.

In April 2022, AngioDynamics, Inc. announced a new clinical study to assess its Auryon Atherectomy system to treat calcified lesions in below-the-knee arteries. AngioDynamics believes that the study will further enhance and confirm the efficacy and versatility of Auryon while effectively treating patients and helping them improve their way of life.

In February 2022, Cardiovascular Systems, Inc. (CSI) announced its collaboration with Innova Vascular, Inc. to develop a full line of novel thrombectomy devices. Innova believes that the collaboration with CSI would allow it to leverage CSI’s commercial presence in the thrombectomy devices market to accelerate the commercialization of Innova’s products after receiving regulatory clearances.

In November 2021, Avinger Inc. announced it had received FDA 510 (k) clearance for its Pantheris image-guided atherectomy system to treat in-stent restenosis in the lower extremity arteries. Avinger believes that the clearance will allow the company to expand its addressable market to include a high-incidence disease state for which only a few treatment options are available.

In October 2021. Becton, Dickinson, and Company (BD Interventional) announced that it had received FDA 510 (k) clearance for its Rotarex Atherectomy System to treat in-stent restenosis in peripheral arteries. BD believes that the clearance will provide physicians with an ideal solution to treat complex lesions associated with peripheral artery disease and demonstrates its responsibility to develop new technology to fight against peripheral artery disease.

In September 2021, Boston Scientific Corporation announced the acquisition of Devoro Medical for approximately USD 336 million. Boston Scientific believes that the acquisition of Devoro will allow it to leverage Devoro’s WOLF thrombectomy platform to advance its efforts to ensure clinicians have the necessary tools to improve product efficiency.

Various Leading Atherectomy Devices that Key Market Leaders Develop

Name of the Product	Function	Key Player
Auryon Atherectomy System Catheter	Treatment of above-the-knee calcified lesions	AngioDynamics
Pantheris	Image-Guided Atherectomy	Avinger, Inc.
Crosser Catheter S6	Facilitates intraluminal placement of conventional guidewires beyond peripheral artery chronic total occlusions (CTO) via atherectomy	Becton, Dickinson, and Company (BD Interventional)
Turbo-Elite Laser Atherectomy Catheter	Treatment of multiple lesion morphologies within PAD lesions using ultraviolet radiation	Koninklijke Philips NV
Revolutionary Peripheral Atherectomy System	Ablation and removal of thrombus and atherosclerotic plaque from peripheral arteries	Rex Medical, Inc.

Frequently Asked Question About This Report

b: The types of atherectomy are directional, rotational, orbital, and laser atherectomy.

b: The success rate of atherectomy was found to be greater than 96%.

b: The global atherectomy devices market is expected to grow at a compound annual growth rate (CAGR) of 7.34% from 2021 to 2030 to reach USD2.01 billion by 2030.

b: Orbital atherectomy is an adjunctive process used to prepare lesions before percutaneous coronary infection and peripheral percutaneous endovascular intervention.

b: The global atherectomy devices market size was $1.06 Bn in 2021 and is predicted to reach $2.01 Bn by 2030, with a CAGR of 7.34%.

b: Atherectomy devices are those devices that are used to remove the thrombus and plaque from a blood vessel.

b: The laser product segment across the market is witnessing significant expansion because it is found to be suitable for clinical benefits offered and the ongoing increasing developments of directional atherectomy technology.

Sources

https://www.ahajournals.org/doi/10.1161/01.cir.102.21.2593

https://www.healthline.com/health/vitrectomy

https://www.ncbi.nlm.nih.gov/books/NBK557482/

https://www150.statcan.gc.ca/n1/daily-quotidien/220822/dq220822b-eng.htm

https://www.ahajournals.org/doi/10.1161/01.CIR.96.1.128